# Tesamorelin and visceral fat · PepVault guides

Source: https://pepvault.app/guides/tesamorelin-and-visceral-fat

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [The science](https://pepvault.app/guides#science)

# Tesamorelin and visceral fat: the approved use and the trials

Reviewed November 2026 15 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Tesamorelin cut deep belly fat about 15% more than placebo in two phase 3 HIV trials, with no weight loss. The approved use, how it works, what came back.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 15
- **Questions:** 10
- **Compounds:** 2

## The short answer

Tesamorelin is a lab-made version of the body's growth hormone-releasing hormone, FDA-approved since 2010 for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. In two phase 3 trials, 26 weeks of daily injections cut visceral fat, the deep fat around the organs, about 15% more than placebo, while body weight stayed flat. Six months after stopping, most of it had returned.

Every number checked at its primary source · Nov 20, 2026 · [15 sources](https://pepvault.app/guides/tesamorelin-and-visceral-fat#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Human trials: two large placebo-controlled phase 3 trials in 806 adults with HIV and their 26-week extensions, plus smaller randomized trials of liver fat in HIV (50 and 61 people), abdominal obesity (60 people) and older adults (152 people).

## What is tesamorelin?

Tesamorelin is the body's full 44-amino-acid growth hormone-releasing hormone (GHRH), the hypothalamus's signal for growth hormone, with one addition: a short six-carbon chain attached to its first link[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Sermorelin, its older relative, keeps only the first 29 links of the same chain. The FDA approved tesamorelin on November 10, 2010, as Egrifta[3](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-3).

Two forms are sold today, and their labels give different doses. The EGRIFTA SV label's dose is 1.4 mg once daily, from a 2 mg vial mixed fresh each day; the EGRIFTA WR label's is 1.28 mg once daily, from a vial mixed once a week. The labels say the two are not substitutable, and each was approved on matching blood levels with the original 2 mg dose the trials used[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1) [2](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-2).

The molecule itself is brief. After one injection under the skin, its half-life was 8 minutes for EGRIFTA SV and 11 minutes for EGRIFTA WR, measured in healthy adults[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1) [2](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-2). What lasts is the response it sets off.

Try it

How Tesamorelin builds up

An estimate from a half-life of about 0.2 hours, one dose a day for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Tesamorelin in the library](https://pepvault.app/peptides/tesamorelin)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's body check-ins record your waist, a measure the trials also tracked, so its curve sits beside your scans.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How does tesamorelin reduce visceral fat?

It works one step upstream of growth hormone. Tesamorelin binds the GHRH receptor on the pituitary's growth hormone cells, so the pituitary releases more of its own growth hormone in its usual pulses, and the liver answers with more IGF-1, a growth factor that carries part of growth hormone's effect[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Growth hormone breaks down stored fat, and the deep fat inside the abdomen responded most[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1) [8](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-8).

In the two phase 3 trials, IGF-1 rose by an average of 107 and 108 ng/mL over 26 weeks, while it fell 15 ng/mL and rose 3 ng/mL on placebo[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Other pituitary hormones (thyroid, adrenal, reproductive and prolactin) did not change in a meaningful way[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Because the drug needs a working pituitary, the label rules it out after pituitary surgery, head radiation or other damage to that axis[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).

Outside HIV, a two-week study in 13 healthy men with an average BMI of 27 showed the same pattern: overnight growth hormone pulses grew larger, IGF-1 rose by 181 μg/L, and insulin sensitivity measured by a glucose clamp did not change[12](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-12).

## How much visceral fat did the trials remove?

Visceral fat was measured as an area on a CT slice at the level of the lower spine, in square centimetres. At the start of the phase 3 trials, the average was 176 to 189 cm²[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Every trial in the table gave 2 mg of the original formulation once daily under the skin.

| Trial | Who | Length | Tesamorelin | Placebo |
| --- | --- | --- | --- | --- |
| Phase 2, 2005[4](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-4) | 61 adults with HIV and central fat | 12 weeks | −15.7% (2 mg group) | −5.4% (difference not significant) |
| Phase 3 study 1, 2007[5](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-5) | 412 adults with HIV, 86% men | 26 weeks | −15.2% | +5.0% |
| Phase 3 study 2, 2010[7](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-7) | 404 adults with HIV | 26 weeks | −10.9% (−21 cm²) | −0.6% (−1 cm²) |
| Both phase 3 trials pooled[8](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-8) | 806 adults with HIV | 26 weeks | −24 cm² | +2 cm²; net effect −15.4% |
| Stanley, 2014[9](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-9) | 50 adults with HIV | 6 months | −34 cm² | +8 cm² |
| Makimura, 2012[11](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-11) | 60 adults with abdominal obesity and low growth hormone output | 12 months | −16 cm² | +19 cm² |

Tesamorelin shrank the inner shaded area; the outer ring under the skin did not change significantly.

The label re-analysed the two phase 3 trials with its own model and reports −18% versus +2% for study 1 and −14% versus −2% for study 2[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). The fat just under the skin of the abdomen did not change significantly in the pooled trials or the obesity trial[8](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-8) [11](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-11).

Trial 1 kept going for a second 26 weeks: people who stayed on tesamorelin held a visceral fat reduction of about 18% from their starting scan at week 52[6](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-6).

## With this guide

### Tesamorelin

- [Tesamorelin: the full reference](https://pepvault.app/peptides/tesamorelin)
- [Tesamorelin dose guide](https://pepvault.app/lab/dosage/tesamorelin)

### Sermorelin

- [Sermorelin: the full reference](https://pepvault.app/peptides/sermorelin)
- [Sermorelin dose guide](https://pepvault.app/lab/dosage/sermorelin)

### Mixing charts

- [Tesamorelin 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-2mg)
- [Tesamorelin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-10mg)
- [Sermorelin 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/sermorelin-5mg)

### Studies

- [Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy](https://pepvault.app/research/tesamorelin-badran-2026)
- [Tesamorelin shifted liver gene activity in HIV-related fatty liver](https://pepvault.app/research/tesamorelin-fourman-2020)
- [Tesamorelin: denser, larger trunk muscles at 26 weeks in HIV](https://pepvault.app/research/tesamorelin-adrian-2019)
- [All 12 studies](https://pepvault.app/research#tesamorelin)

### Compared with

- [Sermorelin vs Tesamorelin](https://pepvault.app/peptides/compare/sermorelin-vs-tesamorelin)
- [Ipamorelin vs Tesamorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-tesamorelin)
- [HGH vs Tesamorelin](https://pepvault.app/peptides/compare/hgh-vs-tesamorelin)
- [Ipamorelin vs Sermorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-sermorelin)
- [CJC-1295 no DAC vs Sermorelin](https://pepvault.app/peptides/compare/cjc-1295-no-dac-vs-sermorelin)
- [HGH vs Sermorelin](https://pepvault.app/peptides/compare/hgh-vs-sermorelin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Growth hormone path

- [Sermorelin dosage: what the studies used](https://pepvault.app/guides/sermorelin-dosage-in-studies)
- [HGH dosage: what the labels and the trials used](https://pepvault.app/guides/hgh-dosage-labels-and-trials)
- [Tesamorelin vs retatrutide for belly fat](https://pepvault.app/guides/tesamorelin-vs-retatrutide)
- [AOD-9604: what the human trials found](https://pepvault.app/guides/aod-9604-trials)
- [Can you drink alcohol on growth hormone peptides?](https://pepvault.app/guides/gh-peptides-and-alcohol)

### Terms on this page

- [Vial](https://pepvault.app/glossary/vial)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Growth hormone (GH)](https://pepvault.app/glossary/growth-hormone)
- [GHRH](https://pepvault.app/glossary/ghrh)
- [Placebo](https://pepvault.app/glossary/placebo)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

## Does visceral fat come back after stopping tesamorelin?

Yes, within six months. At week 26 of each phase 3 trial, people who had been on tesamorelin were re-randomized, without knowing which they got, to keep going or switch to placebo. Over the next 26 weeks, visceral fat in the switched groups rose 25 cm² (22%) in study 1 and 24 cm² (16%) in study 2. In the groups that continued, it changed by +3 cm² and −11 cm²[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).

IGF-1 told the same story, falling by 137 and 135 ng/mL after the switch to placebo[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). The authors of study 2 put it plainly: the improvements "were rapidly lost" in those who switched[7](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-7). The effect lasts as long as the daily injections do[6](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-6).

Look at week 26: the line that switches to placebo climbs back toward where it started, the line that continues stays down.

## Does tesamorelin cause weight loss?

No, and the label says so in its first section: it is "not indicated for weight loss management as it has a weight neutral effect"[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Over 26 weeks, average weight changed by −0.4 kg and +0.5 kg in the two trials, no different from placebo[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).

What changed was where the weight sat. Trunk fat fell 1.0 kg and 0.8 kg, lean body mass rose 1.3 kg and 1.2 kg, and the waist shrank an average of 3 cm and 2 cm, against 1 cm on placebo[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Fat came off the middle, lean tissue went on, and the scale barely moved.

The scale stays nearly flat: the fat that came off the trunk is roughly matched by the lean tissue gained.

## What did tesamorelin do to liver fat?

Two smaller trials in people with HIV measured liver fat directly. In the 2014 trial of 50 adults with abdominal fat, 6 months of tesamorelin lowered the liver's lipid-to-water ratio by a median of 2.0 points while it rose 0.9 on placebo[9](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-9). In the 2019 trial of 61 adults with fatty liver disease, 12 months cut the liver fat fraction by 4.1 points more than placebo, a 37% relative drop, and 35% of the tesamorelin group fell below the 5% line the trial used to enrol, against 4% on placebo[10](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-10). Fasting glucose and HbA1c did not differ between groups at 12 months[10](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-10).

## Does tesamorelin work outside HIV?

Yes, in a 12-month controlled trial recruited for obesity rather than HIV. Makimura and colleagues gave tesamorelin or placebo to 60 adults aged 18 to 55 with a BMI of 30 or more, a waist of at least 102 cm in men or 88 cm in women, a peak growth hormone of 8 ng/mL or less on a stimulation test, and no diabetes[11](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-11) [15](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-15). Visceral fat fell 16 cm² against a 19 cm² rise on placebo, triglycerides and C-reactive protein (a marker of inflammation) fell, the carotid artery wall thinned slightly, and fasting glucose and HbA1c did not change[11](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-11).

A second trial looked at the brain rather than the belly. In 152 adults aged 55 to 87, 66 of them with mild cognitive impairment, tesamorelin at 1 mg each night for 20 weeks improved a combined cognition score and executive function, raised IGF-1 by 117% within the normal range, and lowered percent body fat by 7.4% on a DXA scan. Fasting insulin rose 35% in the group with cognitive impairment, still within the normal range[14](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-14).

These are two trials in selected groups. The label's approval rests on the HIV trials, and the label adds that long-term cardiovascular safety has not been established[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).

## What does the label ask doctors to monitor?

Three things, because growth hormone raises IGF-1 and can raise blood sugar[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1):

1. Before your first dose, you have your blood sugar checked; the trials enrolled only people with fasting glucose under 150 mg/dL who were not on diabetes medicine[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).
2. During treatment, you have IGF-1 measured at intervals. In the trials, 47% of people had IGF-1 above 2 standard deviation scores (above the usual range for their age) at 26 weeks, and the label suggests considering stopping if it stays above 3, especially when the fat response is weak[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).
3. You have blood sugar rechecked periodically. HbA1c reached 6.5% or higher in 5% of people on tesamorelin and 1% on placebo[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).
4. Along the way, you and your prescriber judge the response: the label asks them to weigh continuing in people whose visceral fat has not come down[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). In a later analysis of the phase 3 trials, people whose visceral fat fell 8% or more kept steadier fasting glucose and HbA1c over 52 weeks than those whose fat fell less[13](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-13).

<!--promo-->

PepVault's body check-ins record your waist, a measure the trials also tracked, so its curve sits beside your scans. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-tesamorelin-and-visceral-fat-inlin&mt=8)

<!--/promo-->

<!--promo-->

Its bloodwork log takes IGF-1, fasting glucose and HbA1c, the numbers behind the label's monitoring. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-tesamorelin-and-visceral-fat-inlin&mt=8)

<!--/promo-->

The label also rules tesamorelin out in active cancer, since growth hormone is a growth factor, and in pregnancy, where shrinking visceral fat offers no benefit and could harm the baby[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).

## What are the side effects of tesamorelin?

Most involve the skin and joints. These are the label's rates over the first 26 weeks of both trials[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1):

| Effect | Tesamorelin (543 people) | Placebo (263 people) |
| --- | --- | --- |
| Injection site reaction (redness, itch, pain) | 17% | 6% |
| Joint pain | 13% | 11% |
| Pain in an arm or leg | 6% | 5% |
| Muscle aches | 6% | 2% |
| Swelling in the legs or feet | 6% | 2% |
| Tingling | 5% | 2% |
| Numbness | 4% | 2% |

The label links the joint aches and swelling to fluid retention from the extra growth hormone, and notes they either pass or resolve once treatment stops[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). Counting every kind of skin reaction at the site, the label's rate is 25% against 14%, and rotating injection sites across the abdomen reduces them[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). If an allergic reaction is suspected (hives, itching, flushing or a rash beyond the injection site), the label's advice is to stop the drug and get prompt medical care[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1).

## What do people who use tesamorelin report?

**Commonly reported:** a smaller waist and flatter belly while the scale barely moves, redness or itching where the injection went in, and achy joints in the first weeks that ease with time.

These are user reports, not trial results, though they match the trials' pattern of a smaller waist without weight loss[1](https://pepvault.app/guides/tesamorelin-and-visceral-fat#source-1). The sermorelin guide in this series covers how the shorter GHRH copy was dosed in its own studies.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. EGRIFTA WR (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, SPL version 2, published Aug 3, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
2. EGRIFTA SV (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, SPL version 9, published Jul 31, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224)
3. U.S. Food and Drug Administration. Drugs@FDA: Egrifta (tesamorelin), application 022505, original approval November 10, 2010. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505)
4. Falutz J et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005. [PubMed 16052083](https://pubmed.ncbi.nlm.nih.gov/16052083/)
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. [PubMed 18057338](https://pubmed.ncbi.nlm.nih.gov/18057338/)
6. Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008. [PubMed 18690162](https://pubmed.ncbi.nlm.nih.gov/18690162/)
7. Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010. [PubMed 20101189](https://pubmed.ncbi.nlm.nih.gov/20101189/)
8. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. [PubMed 20554713](https://pubmed.ncbi.nlm.nih.gov/20554713/)
9. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. [PubMed 25038357](https://pubmed.ncbi.nlm.nih.gov/25038357/)
10. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019. [PubMed 31611038](https://pubmed.ncbi.nlm.nih.gov/31611038/)
11. Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012. [PubMed 23015655](https://pubmed.ncbi.nlm.nih.gov/23015655/)
12. Stanley TL et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011. [PubMed 20943777](https://pubmed.ncbi.nlm.nih.gov/20943777/)
13. Stanley TL et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012. [PubMed 22495074](https://pubmed.ncbi.nlm.nih.gov/22495074/)
14. Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012. [PubMed 22869065](https://pubmed.ncbi.nlm.nih.gov/22869065/)
15. ClinicalTrials.gov NCT00675506. Effectiveness of growth hormone releasing hormone in reducing abdominal fat in people who are obese. Massachusetts General Hospital. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00675506)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · Growth hormone

Guide · Growth hormone

### [HGH dosage: what the labels and the trials used](https://pepvault.app/guides/hgh-dosage-labels-and-trials)

HGH dosage on the FDA labels: 0.2 mg (0.6 IU) a day to start in adult deficiency, up to 6 or 8 mg in HIV wasting and short bowel, with IU and side effects.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Tesamorelin Studied range: 1–2 mg](https://pepvault.app/peptides/tesamorelin)
- [Sermorelin Studied range: 200–500 mcg](https://pepvault.app/peptides/sermorelin)

## Related guides

- Guide · The science

  ### [Sermorelin dosage: what the studies used](https://pepvault.app/guides/sermorelin-dosage-in-studies)

  Sermorelin dosage in studies: 1 mcg/kg IV for testing, 30 mcg/kg nightly in children, 0.5 to 2 mg in older men. How it works and what users report.

  Read the guide
- Guide · Getting started

  ### [Where to inject peptides under the skin](https://pepvault.app/guides/where-to-inject-peptides)

  Where to inject subcutaneous peptides: belly, thigh or upper arm, how far from the navel, why rotating sites matters, and what is normal at the site after.

  Read the guide
- Guide · Stacks

  ### [What to take alongside each peptide](https://pepvault.app/guides/what-to-take-with-peptides)

  What to pair with each peptide, and why: glycine and vitamin C for repair, less zinc on GHK-Cu, fasting and sleep for GH peptides, protein on GLP-1s.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Tesamorelin

- [Tesamorelin: the full reference](https://pepvault.app/peptides/tesamorelin)
- [Tesamorelin dose guide](https://pepvault.app/lab/dosage/tesamorelin)

### Sermorelin

- [Sermorelin: the full reference](https://pepvault.app/peptides/sermorelin)
- [Sermorelin dose guide](https://pepvault.app/lab/dosage/sermorelin)

### Mixing charts

- [Tesamorelin 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-2mg)
- [Tesamorelin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-10mg)
- [Sermorelin 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/sermorelin-5mg)

### Studies

- [Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy](https://pepvault.app/research/tesamorelin-badran-2026)
- [Tesamorelin shifted liver gene activity in HIV-related fatty liver](https://pepvault.app/research/tesamorelin-fourman-2020)
- [Tesamorelin: denser, larger trunk muscles at 26 weeks in HIV](https://pepvault.app/research/tesamorelin-adrian-2019)
- [All 12 studies](https://pepvault.app/research#tesamorelin)

### Compared with

- [Sermorelin vs Tesamorelin](https://pepvault.app/peptides/compare/sermorelin-vs-tesamorelin)
- [Ipamorelin vs Tesamorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-tesamorelin)
- [HGH vs Tesamorelin](https://pepvault.app/peptides/compare/hgh-vs-tesamorelin)
- [Ipamorelin vs Sermorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-sermorelin)
- [CJC-1295 no DAC vs Sermorelin](https://pepvault.app/peptides/compare/cjc-1295-no-dac-vs-sermorelin)
- [HGH vs Sermorelin](https://pepvault.app/peptides/compare/hgh-vs-sermorelin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Growth hormone path

- [Sermorelin dosage: what the studies used](https://pepvault.app/guides/sermorelin-dosage-in-studies)
- [HGH dosage: what the labels and the trials used](https://pepvault.app/guides/hgh-dosage-labels-and-trials)
- [Tesamorelin vs retatrutide for belly fat](https://pepvault.app/guides/tesamorelin-vs-retatrutide)
- [AOD-9604: what the human trials found](https://pepvault.app/guides/aod-9604-trials)
- [Can you drink alcohol on growth hormone peptides?](https://pepvault.app/guides/gh-peptides-and-alcohol)

### Terms on this page

- [Vial](https://pepvault.app/glossary/vial)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Growth hormone (GH)](https://pepvault.app/glossary/growth-hormone)
- [GHRH](https://pepvault.app/glossary/ghrh)
- [Placebo](https://pepvault.app/glossary/placebo)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
